Cardio Diagnostics Holdings, Inc.
CDIO · XNASCIK 1870144fmd_011Q45F85FMTBN34ZVR1ETE6YMManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 21 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 |
| Research and development | 0 | 0 | 0 | 0 | 1 |
| Selling, general and administrative | 1 | 4 | 7 | 8 | 6 |
| Total operating expenses | 1 | 5 | 7 | 8 | 6 |
| Operating income | (1) | (5) | (7) | (8) | (6) |
| Interest expense | – | – | 7 | 0 | 0 |
| Other non-operating income (expense) | – | (0) | (1) | (0) | (0) |
| Income before taxes | (1) | (5) | (8) | (8) | (6) |
| Income tax expense | 0 | 0 | – | – | – |
| Net income from continuing operations | (1) | (5) | – | – | – |
| Net income | (1) | (5) | (8) | (8) | (6) |
| Net income to common shareholders | 1 | 5 | – | – | – |